RecruitingNCT06698692

Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma

Real-world Assessment of Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Enrollment

200 participants

Start Date

Apr 2, 2024

Study Type

OBSERVATIONAL

Conditions

ESCC

Summary

Clinical data of patients with synchronous radiotherapy for esophageal cancer in the Department of Radiology of Jiangsu Provincial People's Hospital were collected. Patients were divided into trilaciclib group (34 cases) and control group (169 cases) based on whether trilaciclib was used or not. Patients in the trilaciclib group were given trilaciclib before each chemotherapy treatment. Propensity score matching (PSM) was used to balance the baseline characteristics between the two groups on a 1:1 ratio. After pairing, the rates of bone marrow suppression and other adverse events were compared between the two groups.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a drug called trilaciclib, given before chemoradiotherapy, can protect bone marrow and reduce low blood cell counts (a common and dangerous side effect) in people with esophageal squamous cell carcinoma (cancer of the food pipe). **You may be eligible if...** - You are 18 years or older - You have been diagnosed with esophageal squamous cell carcinoma confirmed by pathology - Surgical treatment is not an option for you - You have completed or are completing standard chemoradiotherapy, with or without immunotherapy **You may NOT be eligible if...** - You have had another type of cancer - You have insufficient clinical records or will be difficult to follow up over time Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.